Scientific Advisors
Dennis Roop, Ph.D.
Professor of Dermatology and Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology at the University of Colorado School of Medicine (UCD). Dr. Roop’s expertise in stem cell biology will be key in advancing Taiga’s programs related to the development of a universal donor hematopoietic stem cell line.
Peter Kiener, Ph.D.
President and CEO of Zyngetia. Prior to joining Zyngentia, Dr. Kiener served as the executive vice president of biologics and global head of biologics R&D at AstraZeneca PLC/MedImmune. Dr. Kiener has expertise in the area of antibody-based therapeutics as well as the design and implementation of clinical trials. His expertise will be key in the advancement of Taiga’s fully-human therapeutic antibody platform.
Frank Malinoski, M.D., Ph.D.
Chief medical officer at Liquidia Technologies, Inc. Prior to Liquidia, he was the senior vice president of vaccine development at MedImmune and has over 20 years of experience in the development and deployment of novel vaccines in civilian and military applications. Dr. Malinoski has over 20 years of experience in the development and deployment of novel vaccines in civilian and military applications. His expertise will help Taiga advance its novel immune enhancer into areas of significant unmet medical need.
Jack McGuire
Former President and CEO of the American Red Cross (ARC). Prior to that, Mr. McGuire’s career included more than 22 years as a leader in the biomedical field, including senior executive positions at companies including Whatman PCL-North America, Hemasure, Inc. and Johnson & Johnson’s Ortho Diagnostics. Mr. McGuire’s extensive business experience relating to hematology and other critical medical products will be vital for advancing Taiga’s red blood cell pharming technology platform.
